Bora Pharmaceuticals

TAI:6472 · TW0006472004

PharmaceuticalsMedium

360

Value46

Profit price36

EV / EBIT52

Price / Owner Earnings20

Cash yield75

Owner Earnings Yield55

Dividend Yield95

Sales & asset price29

Price/Sales35

EV / Gross Profit31

Price/Book20

Quality56

Returns on capital60

Return on Capital63

Cash Return on Capital50

Return on Equity67

Profit margins48

EBIT Margin64

Gross Profitability32

Cash backing56

Cash Conversion75

Accruals38

Owner Earnings Margin55

Growth47

Sales growth92

Profit growth43

Profit Growth77

Long-Term EPS Growth27

Owner Earnings Growth26

Reinvestment77

Price momentum3

Safety32

Debt load7

Debt serviceability21

Refinancing28

Debt Payback13

Liquidity57

Sentiment44

Analyst ratings27

Expectations trend62

Opinion Changes50

Price Target Upside74

Market mood73

Value Creation8/20creating some value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Bora Pharmaceuticals clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryTaiwan

IndustryPharmaceuticals

SizeMedium

TypePublic Company

ExchangeTWSE

Founded2007

Employees592

Websitebora-corp.com

ISINTW0006472004

Last UpdateApr 2, 2026

Indices

FTSE Taiwan Index (Taiwan)

Themes

Pain ManagementNutraceuticalCentral Nervous SystemPharmaceutical

Description

Bora Pharmaceuticals Co., Ltd. engages pharmaceutical manufacturing, wholesaling, and various healthcare products. Business Segments The company operational structure is segmented into vital areas that align closely with its strategic goals. The pr…

Analysis

Middle-of-the-road

Bora Pharmaceuticals Co., Ltd. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

On valuation, the picture is expensive. The owner-earnings multiple stands at 32.3×; owner earnings: the cash an owner could take out each year.

Growth is moderate; the safety picture is stretched. The company scores 8/20 on our value-creation score: creating some value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250

2026

All-time high

Jun 2026

All-time low

Mar 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Bora Pharmaceuticals with its peers

Boryung

KSC:003850

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Kukje Pharma

KSC:002720

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Reyon Pharmaceutical

KSC:102460

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Kyongbo Pharmaceutical

KSC:214390

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Hanall Biopharma

KSC:009420

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Chongkundang Holdings

KSC:001630

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →